| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2012: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2011: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Research Abstract |
We conducted experimental studies to investigate anti-tumor activity of a poly-ADP-ribose polymerase (PARP) 1 inhibitor olaparib and a mTOR inhibitor everolimus (EVE) using breast cancer cell lines. We also investigated the effects of the agents on the ratio of CSC. Olaparib possesses growth inhibitory activity in not only TNBC cell lines but also ER-positive, HER2-negative cell lines. A combined treatment of olaparib with antiestrogen (AE) rendered an additive growth inhibitory effect in ER-positive cell lines. Anti-tumor activity of EVE was investigated using a panel of human breast cancer cell lines of various subtypes. EVE possessed a drastic growth inhibitory effect on a BRCA1-mutated, TNBC cell line and also exhibited a moderate growth inhibitory effect on a part of ER-positive breast cancer cells lines. EVE tended to decrease the ratio of CSC in most cell lines.
|
